Bayesian Evaluation of Treatment Effect of Avelumab Plus Axitinib for Advanced Renal Cell Carcinoma
Cancer Medicine · 2026-06 · 15 (6)
DOI: 10.1002/cam4.71999 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 29.05.2026. Verfasst von Wataru Fukuokaya und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Axitinib, Kidney Neoplasms, Antibodies, Monoclonal, Humanized. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Despite not achieving statistical significance, the JAVELIN Renal 101 trial indicated a potentially clinically relevant effect size (hazard ratio [HR], 0.88; 95% confidence interval, 0.75 to 1.04) on overall survival (OS) favoring avelumab plus axitinib over sunitinib for advanced renal cell carcinoma (aRCC). To better interpret these findings, we performed a Bayesian evaluation.
Methods
We reanalyzed individual participant data from the JAVELIN Renal 101 trial using a Bayesian framework. Prior distributions were specified for varying levels of enthusiasm and skepticism for avelumab plus axitinib, and a prior from a meta‐analysis of similar trials. The posterior probability of any OS benefit with avelumab plus axitinib, Pr(HR < 1.0), and of benefit exceeding the minimal clinically important difference (MCID; HR = 0.75), Pr(HR < MCID), were estimated using Bayesian Cox models. Bayesian hierarchical models evaluated treatment effect heterogeneity across International Metastatic Renal Cell Carcinoma Database Consortium risk groups and programmed death‐ligand 1 (PD‐L1) status.
Results
Regardless of the prior assumptions used, Pr(HR < 1.0) was consistently high (93.0% to 95.5%). However, Pr(HR < MCID) was low (1.0% to 3.8%). Results were similar when the prior was informed by pooled data from similar trials. In subgroup analyses, Pr(HR < MCID) varied by risk group: 63.4% for poor‐risk, 34.9% for favorable‐risk, and 0.9% for intermediate‐risk aRCC. This probability was low regardless of PD‐L1 status.
Conclusions
This exploratory Bayesian reanalysis complements the interpretation of the JAVELIN Renal 101 trial and offers a probabilistic perspective beyond a dichotomous (i.e., significant/nonsignificant) interpretation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, The Jikei University School of Medicine, Tokyo, Japan.
- Department of Clinical Biostatistics, Graduate School of Medical and Dental Science, Institute of Science Tokyo, Tokyo, Japan.
- Department of Urology, Medical University of Silesia, Zabrze, Poland.
- Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
- Division of Surgery and Interventional Science, University College London, London, UK.
- Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia.
ORCID-Profile: Wataru Fukuokaya, Takafumi Yanagisawa, Fumihiko Urabe, Takahiro Kimura, Akihiro Hirakawa
Zitieren
APA
Fukuokaya, W., Mori, K., Yanagisawa, T., Ito, K., Imai, Y., Urabe, F., Rajwa, P., Shariat, S. F., Kimura, T., & Hirakawa, A. (2026). Bayesian Evaluation of Treatment Effect of Avelumab Plus Axitinib for Advanced Renal Cell Carcinoma. Cancer Medicine, 15(6). https://doi.org/10.1002/cam4.71999
Vancouver
Fukuokaya W, Mori K, Yanagisawa T, Ito K, Imai Y, Urabe F, et al. Bayesian Evaluation of Treatment Effect of Avelumab Plus Axitinib for Advanced Renal Cell Carcinoma. Cancer Medicine. 2026;15(6). doi:10.1002/cam4.71999
BibTeX
@article{Fukuokaya2026,
author = {Fukuokaya, Wataru and Mori, Keiichiro and Yanagisawa, Takafumi and Ito, Kagenori and Imai, Yu and Urabe, Fumihiko and Rajwa, Pawel and Shariat, Shahrokh F and Kimura, Takahiro and Hirakawa, Akihiro},
title = {Bayesian Evaluation of Treatment Effect of Avelumab Plus Axitinib for Advanced Renal Cell Carcinoma},
journal = {Cancer Medicine},
year = {2026},
volume = {15},
number = {6},
doi = {10.1002/cam4.71999}
}
EUVIMED